Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor. ADMET DMPK [Internet]. 2017 Dec. 23 [cited 2026 Jun. 2];5(4):212-23. Available from: https://pub.iapchem.org/ojs/index.php/admet/article/view/437